Nuvectis Pharma Statistics
Total Valuation
Nuvectis Pharma has a market cap or net worth of $181.43 million. The enterprise value is $164.27 million.
| Market Cap | 181.43M |
| Enterprise Value | 164.27M |
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, before market open.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvectis Pharma has 23.90 million shares outstanding. The number of shares has increased by 10.23% in one year.
| Current Share Class | 23.90M |
| Shares Outstanding | 23.90M |
| Shares Change (YoY) | +10.23% |
| Shares Change (QoQ) | +1.95% |
| Owned by Insiders (%) | 44.44% |
| Owned by Institutions (%) | 6.76% |
| Float | 13.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 13.11 |
| P/TBV Ratio | 16.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.74
| Current Ratio | 2.74 |
| Quick Ratio | 2.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -140.00% and return on invested capital (ROIC) is -87.00%.
| Return on Equity (ROE) | -140.00% |
| Return on Assets (ROA) | -60.86% |
| Return on Invested Capital (ROIC) | -87.00% |
| Return on Capital Employed (ROCE) | -175.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.49M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.97% in the last 52 weeks. The beta is 0.21, so Nuvectis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +7.97% |
| 50-Day Moving Average | 5.98 |
| 200-Day Moving Average | 6.47 |
| Relative Strength Index (RSI) | 62.94 |
| Average Volume (20 Days) | 137,848 |
Short Selling Information
The latest short interest is 1.48 million, so 6.20% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short Previous Month | 1.48M |
| Short % of Shares Out | 6.20% |
| Short % of Float | 11.16% |
| Short Ratio (days to cover) | 15.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.26M |
| Pretax Income | -21.10M |
| Net Income | -19.37M |
| EBITDA | n/a |
| EBIT | -19.26M |
| Earnings Per Share (EPS) | -$1.16 |
Balance Sheet
| Cash & Cash Equivalents | 17.17M |
| Total Debt | n/a |
| Net Cash | 17.17M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 10.99M |
| Book Value Per Share | 0.58 |
| Working Capital | 10.99M |
Cash Flow
| Operating Cash Flow | -13.63M |
| Capital Expenditures | n/a |
| Free Cash Flow | -13.63M |
| FCF Per Share | -$0.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvectis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.23% |
| Shareholder Yield | -10.23% |
| Earnings Yield | -10.68% |
| FCF Yield | -7.51% |
Analyst Forecast
The average price target for Nuvectis Pharma is $21.00, which is 176.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 176.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |